Can I Get a Michigan Medical Marijuana Card for Hepatitis C?

Yes — hepatitis c qualifies under the Michigan Medical Marihuana Program

Hepatitis C is explicitly listed as a Category A qualifying condition on the Michigan MMMP Physician Certification Form. While direct-acting antiviral (DAA) therapy can now cure most HCV infections in 8–12 weeks, patients still experience substantial symptoms during active infection, during DAA therapy, and in some cases after viral cure (post-cure fatigue, persistent joint pain). Medical cannabis is one of the symptom-management options patients use across this disease trajectory.

Common symptoms

• Fatigue (often the most disabling symptom)
• Nausea and reduced appetite
• Abdominal discomfort
• Joint and muscle pain
• Sleep disturbance
• Mood changes
• Side effects of direct-acting antiviral (DAA) treatment

How medical cannabis may help

Cannabinoids address several HCV-related symptoms simultaneously: appetite stimulation (CB1-mediated), antiemetic effects, analgesia for joint and muscle pain, and sleep improvement. Many HCV patients use cannabis specifically because it can replace or reduce reliance on multiple medications — appetite stimulants, antiemetics, sleep aids, and pain medications — each with its own side-effect profile.

Evidence base

Cannabis use in HCV has historically been controversial because some early observational studies suggested daily cannabis use might accelerate liver fibrosis. More recent studies have not consistently replicated this finding. The 2017 NASEM report classified evidence for cannabis in chronic pain as "conclusive or substantial" — relevant to the joint and muscle pain that many HCV patients experience. Patients should discuss frequency and route of administration with their hepatologist given the historical fibrosis concern.

Michigan certification requirements

Documentation of HCV diagnosis from your treating provider (hepatologist, infectious disease physician, or primary care). Recent labs (HCV antibody, HCV RNA viral load, ALT/AST, fibroscan or liver biopsy results if available) and your DAA treatment status are helpful. Coordination with your hepatologist is encouraged.